A Prospective/Retrospective, Observational Follow-up Study of Chronic Hepatitis B With Non-alcoholic Fatty Liver Disease.

Launched by QIN NING · Feb 24, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how non-alcoholic fatty liver disease (NAFLD) affects people who have chronic hepatitis B (CHB). The researchers want to understand the relationship between these two conditions better. To do this, they will invite patients who are over 18 years old and diagnosed with chronic hepatitis B to participate. However, if someone has other liver diseases, excessive alcohol use, or certain infections, they won't be able to join the study.

Participants in the trial will undergo tests, including a special ultrasound that measures liver stiffness and fat levels in the liver. They will also have a thorough medical check-up. The study is currently recruiting participants of all genders, and it aims to gather important information that could help doctors understand how NAFLD impacts patients with chronic hepatitis B. If you or someone you know might be interested, it’s a good opportunity to contribute to important research in liver health.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria: age \> 18 years, chronic hepatitis B patients -
• • Exclusion Criteria: patients with chronic hepatitis C or D and human immunodeficiency virus co-infection, excessive alcohol intake (≥30 g/d for men, ≥20 g/d for women), other chronic liver diseases (e.g. primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, Wilson's disease), or on medications known to induce hepatic steatosis (including corticosteroids, methotrexate, and tamoxifen), and pregnancy.
• • -